104 related articles for article (PubMed ID: 24532335)
1. Long-term outcome of monoclonal (type 1) cryoglobulinemia.
Néel A; Perrin F; Decaux O; Dejoie T; Tessoulin B; Halliez M; Mahé B; Lamy T; Fakhouri F; Jego P; Agard C; Vigneau C; Guenet L; Grosbois B; Moreau P; Hamidou M
Am J Hematol; 2014 Feb; 89(2):156-61. PubMed ID: 24532335
[TBL] [Abstract][Full Text] [Related]
2. Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases.
Trejo O; Ramos-Casals M; López-Guillermo A; García-Carrasco M; Yagüe J; Cervera R; Font J; Ingelmo M
Semin Arthritis Rheum; 2003 Aug; 33(1):19-28. PubMed ID: 12920693
[TBL] [Abstract][Full Text] [Related]
3. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases.
Harel S; Mohr M; Jahn I; Aucouturier F; Galicier L; Asli B; Malphettes M; Szalat R; Brouet JC; Lipsker D; Fermand JP
Br J Haematol; 2015 Mar; 168(5):671-8. PubMed ID: 25363150
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic implications of mixed monoclonal cryoglobulinemia in Sjogren's disease].
Vasil'ev VI; Probatova NA; Varlamova EIu; Tupitsin NN; Simonova MV; Safonova TN; Bozh'eva LA; Shornikova NS; Logvinenko OA; Belenin GIu
Ter Arkh; 2004; 76(8):61-8. PubMed ID: 15471400
[TBL] [Abstract][Full Text] [Related]
5. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia.
Sidana S; Rajkumar SV; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kapoor P; Gonsalves WI; Go RS; Hwa YL; Leung N; Fonder AL; Hobbs MA; Zeldenrust SR; Russell SJ; Lust JA; Kyle RA; Kumar SK
Am J Hematol; 2017 Jul; 92(7):668-673. PubMed ID: 28370486
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
[TBL] [Abstract][Full Text] [Related]
9. Successful use of cryocrit for monitoring response to therapeutic plasma exchange in type 1 cryoglobulinemia.
Olson N; Yerrabothala S; Dunbar N
J Clin Apher; 2016 Aug; 31(4):403-4. PubMed ID: 26194475
[TBL] [Abstract][Full Text] [Related]
10. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
14. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.
Saadoun D; Sellam J; Ghillani-Dalbin P; Crecel R; Piette JC; Cacoub P
Arch Intern Med; 2006 Oct; 166(19):2101-8. PubMed ID: 17060540
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients.
Zhang LL; Cao XX; Shen KN; Han HX; Zhang CL; Qiu Y; Zhao H; Gao XM; Feng J; Zhang L; Zhou DB; Li J
Ann Hematol; 2020 Aug; 99(8):1735-1740. PubMed ID: 32535708
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
19. Acrocyanosis and Progressive Skin Necrosis as Manifestation of Waldenstrom Macroglobulinemia Associated With Type I Cryoglobulinemia: A Case Report.
Nekooghadam SM; Bozorgmehr R; Safavi-Naini SAA
Int J Low Extrem Wounds; 2023 Sep; 22(3):605-609. PubMed ID: 34166124
[TBL] [Abstract][Full Text] [Related]
20. Natural history and therapy of 66 patients with mixed cryoglobulinemia.
Bryce AH; Kyle RA; Dispenzieri A; Gertz MA
Am J Hematol; 2006 Jul; 81(7):511-8. PubMed ID: 16755564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
